Shares Magazine
9.51p-0.09 (-0.97%)25 Apr 2024, 09:56
Jump to:
Scancell Holdings PLC Fundamentals
| Company Name | Scancell Holdings PLC | Last Updated | 2024-04-25 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 928.980 m | Market Cap | £88.32 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.01 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.8905 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | -2.6608 | Cash Equity Ratio | -1.5639 |
| Quick Ratio | 6.8807 | Current Ratio | 8.63 |
| Price To Book Value | 0 | ROCE | 0 |
Scancell Holdings PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Scancell Holdings PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | £2.25 m | £2.74 m | £975,000.00 |
| Intangible Assets | £3.42 m | £3.42 m | £3.42 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £5.66 m | £6.16 m | £4.39 m |
| Stocks | 0 | 0 | 0 |
| Debtors | 0 | 0 | £968,000.00 |
| Cash & Equivalents | £19.92 m | £28.73 m | £41.11 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £30.27 m | £38.52 m | £49.06 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £3.28 m | £2.45 m | £2.29 m |
| Creditors after 1 year | £33.23 m | £31.26 m | £38.08 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £36.50 m | £33.71 m | £40.37 m |
| Net assets | -£6.23 m | £4.81 m | £8.69 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £819,000.00 | £815,000.00 | £815,000.00 |
| Share Premium | £65.18 m | £65.02 m | £65.02 m |
| Profit / Loss | -£14.30 m | -£6.27 m | -£16.80 m |
| Other Equity | -£6.23 m | £4.81 m | £8.69 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | -£6.23 m | £4.81 m | £8.69 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | 0 | £0.80 | £0.64 |
| Debt-to-Equity | 0 | £3.89 | £1.75 |
| Assets / Equity | -2.6608 | -2.6608 | -2.6608 |
| Cash / Equity | -1.5639 | -1.5639 | -1.5639 |
| EPS | -£0.01 | -£0.01 | -£0.02 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -£8.14 m | -£10.19 m | -£7.80 m |
| Cashflow before financing | -£8.89 m | -£11.12 m | £38.28 m |
| Increase in Cash | -£8.80 m | -£12.38 m | £37.53 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | £5.27 m | 0 | 0 |
| Cost of sales | £525,000.00 | 0 | 0 |
| Gross Profit | £4.75 m | 0 | 0 |
| Operating Profit | -£11.92 m | -£13.30 m | -£8.83 m |
| Pre-Tax profit | -£14.30 m | -£6.27 m | -£16.80 m |
Scancell Holdings PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system. |
| Latest Interim Date | 30 Jan 2024 |
| Latest Fiscal Year End Date | 24 Oct 2023 |
Scancell Holdings PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2018-08-31 | Ms. Kate Cornish-Bowden | Non-Executive Director |
| 2016-09-16 | Mr. David Eric Evans | Non-Executive Director,Chairman |
| 2014-05-09 | Mr. Peter Vance Allen | Non-Executive Director |
| 2023-02-01 | Dr. John Chiplin | Executive Director,Chairman |
| 2023-10-31 | Professor Linda Gillian Durrant | Executive Director,Chief Executive Officer and Chief Scientific Officer |
| 2022-10-28 | Dr. Richard Morley Goodfellow | Non-Executive Director |
| 2012-12-12 | Mr. Nigel James Forrester Evans | Non-Executive Director,Company Secretary |
| 2013-02-27 | Mr. Thomas Michael Rippon | Non-Executive Director |
| 2019-10-31 | Dr. Matthew Gerrard Winston Frohn | Non-Executive Director |
| 2023-12-01 | Mr. Martin Henry Diggle | Non-Executive Director |
| 2024-02-05 | Dr. Sally Elizabeth Adams | Executive Director,Development Director |
| 2021-07-28 | Dr. Clifford Michael Holloway | Executive Director,Chief Executive Officer |
| 2023-04-21 | Ms. Susan Elizabeth Clement-Davies | Non-Executive Director,Deputy Chairman |
| 2023-12-06 | Dr. Jean Michel Cossery | Executive Director,Chairman |
Scancell Holdings PLC Contact Details
| Company Name | Scancell Holdings PLC |
|---|---|
| Address | Robert Robinson Avenue, John Eccles House, Oxford Science Park, Oxford, OX4 4GP |
| Telephone | +44 1865338069 |
| Website | https://www.scancell.co.uk |
Scancell Holdings PLC Advisors
| Nominated Adviser | Panmure Gordon (UK) Ltd |
|---|---|
| Phone | +44 2078862500 |
| Stockbroker | Panmure Gordon (UK) Ltd |
|---|---|
| Phone | +44 2078862500 |
| Financial PR Adviser | FTI Consulting Inc |
|---|---|
| Phone | +44 2037271000 |
| Fax | +44 2037271007 |
| Solicitor | Laytons |
|---|---|
| Phone | (020) 7842 8000 |
| Fax | (020) 7842 8080 |
| Registrar | S.L.C Registrars Ltd |
|---|---|
| Phone | +44 1903706150 |
| Financial PR Adviser | Visible Value LLP |
|---|
| Auditor | Champion Accountants LLP |
|---|---|
| Phone | (01244) 404 420 |
| Fax | (01244) 404 440 |
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Anglo American PLC | 2,489.77 | 12.91 |
| Inchcape PLC | 775.50 | 7.86 |
| Puretech Health PLC | 224.00 | 5.41 |
| Unilever PLC | 4,066.00 | 5.26 |
| Astrazeneca PLC | 11,940.00 | 5.18 |
| Barclays PLC | 198.04 | 3.61 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Moonpig Group PLC | 158.00 | -11.04 |
| Trainline PLC | 319.51 | -6.85 |
| Legal & General Group PLC | 237.20 | -4.59 |
| Indivior PLC | 1,446.00 | -4.49 |
| Wh Smith PLC | 1,202.00 | -4.45 |
| Morgan Sindall Group PLC | 2,215.00 | -3.28 |